Tweets by FSCDR's 17th Annual SCD Research and Educational Symposium & 46th Nat'l SCD Scientific Meeting

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Stream

NOTE: All events are in Eastern Daylight Time Zone. Please visit your Symposium Profile to verify your time zone. We recommend displaying all times in the event time zone.

Investigational and Therapeutic Drugs

Oral Abstract Presentation Session ll Trials / Clinical Epidemiology

Hibiscus-Kids: A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease

Sunday, June 18, 2023

4:15 PM – 4:30 PM East Coast USA Time

Location: Grand Salon E

Speaker(s)

Leila Jerome Clay, MD (she/her/hers)

Global International Medical Director
Novo Nordisk Inc.
Watertown, Massachusetts, United States

Slides

First Author(s)

Leila Jerome Clay, MD (she/her/hers)

Global International Medical Director
Novo Nordisk Inc.
Watertown, Massachusetts, United States

Slides

Author(s)

Julie Kanter, MD

Director, Adult Sickle Cell Program; Associate Professor
Division of Hematology and Oncology, University of Alabama Birmingham
University of AL Birmingham
Birmingham, Alabama, United States
MA

Miguel R. Abboud, MD

Professor and Chairman
American University of Beirut Medical Center, Beirut, Lebanon
Beirut, Beyrouth, Lebanon
EW

Eric Wu, PhD

Associate Director Biostatistics
NOVO NORDISK A/S
Watertown, Massachusetts, United States
Leila Jerome Clay, MD (she/her/hers)

Global International Medical Director
Novo Nordisk Inc.
Watertown, Massachusetts, United States

Slides

Corresponding Author(s)

AI

Adlette Inati, MD, FAAP

Professor of Clinical Medicine
Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Department of Pediatrics and Adolescent Medicine, Beirut, Lebanon
Tripoli, Liban-Nord, Lebanon

Author(s)

AI

Adlette Inati, MD, FAAP

Professor of Clinical Medicine
Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Department of Pediatrics and Adolescent Medicine, Beirut, Lebanon
Tripoli, Liban-Nord, Lebanon

Disclosure(s):

Leila Jerome Clay, MD: No relevant disclosure to display

Learning Objectives:

Upon completion, participant will be able to know about the Hibiscus-kids study and its design.
Upon completion, participant will be able to know about theHibiscus-kids study objectives and Endpoints.
Upon completion, participant will be able to know about etavopivat as an investigational, once-daily, oral, selective activator of the RBC-specific isoform of the pyruvate kinase enzyme (PKR).